- Home
- GWRS vs VNDA Comparison
GWRS vs VNDA Comparison
Compare GWRS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- VNDA
- Stock Information
- Founded
- GWRS 2003
- VNDA 2002
- Country
- GWRS United States
- VNDA United States
- Employees
- GWRS N/A
- VNDA N/A
- Industry
- GWRS Water Supply
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- GWRS Utilities
- VNDA Health Care
- Exchange
- GWRS Nasdaq
- VNDA Nasdaq
- Market Cap
- GWRS 268.4M
- VNDA 249.4M
- IPO Year
- GWRS 2010
- VNDA 2006
- Fundamental
- Price
- GWRS $10.03
- VNDA $4.75
- Analyst Decision
- GWRS
- VNDA Strong Buy
- Analyst Count
- GWRS 0
- VNDA 2
- Target Price
- GWRS N/A
- VNDA $16.50
- AVG Volume (30 Days)
- GWRS 64.9K
- VNDA 551.9K
- Earning Date
- GWRS 08-13-2025
- VNDA 07-31-2025
- Dividend Yield
- GWRS 3.12%
- VNDA N/A
- EPS Growth
- GWRS N/A
- VNDA N/A
- EPS
- GWRS 0.22
- VNDA N/A
- Revenue
- GWRS $54,270,000.00
- VNDA $203,467,000.00
- Revenue This Year
- GWRS $8.31
- VNDA $16.86
- Revenue Next Year
- GWRS $6.52
- VNDA $39.78
- P/E Ratio
- GWRS $46.01
- VNDA N/A
- Revenue Growth
- GWRS 4.33
- VNDA 11.78
- 52 Week Low
- GWRS $9.37
- VNDA $3.81
- 52 Week High
- GWRS $13.98
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- GWRS 52.21
- VNDA 60.39
- Support Level
- GWRS $9.65
- VNDA $4.47
- Resistance Level
- GWRS $9.96
- VNDA $4.88
- Average True Range (ATR)
- GWRS 0.26
- VNDA 0.16
- MACD
- GWRS 0.02
- VNDA 0.05
- Stochastic Oscillator
- GWRS 54.81
- VNDA 82.43
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.